China
Africa
Explore chapters and articles related to this topic
Prediction and Analysis of SARS-CoV-2 (COVID-19) epidemic in India using LSTM Network
Published in S. Prabha, P. Karthikeyan, K. Kamalanand, N. Selvaganesan, Computational Modelling and Imaging for SARS-CoV-2 and COVID-19, 2021
A. Ganesh Ram, S. Prabha, M. Vijayakarthick
The first SARS-CoV-2-positive case in India was reported in the state of Kerala on 30th January, 2020. According to the press release by the Indian Council of Medical Research (ICMR), the cumulative total samples tested up to 31st July, 2020 were 19,358,659 by 1,339 government and private laboratories in India. The ICMR reported the samples were tested in Real-Time RT PCR for COVID-19 in 684 laboratories (Govt.: 416 + Private 268), TrueNat Test for COVID-19 in 551 laboratories (Govt.: 465 + Private: 86) and CBNAAT Test for COVID-19 in 104 laboratories (Govt.: 30 + Private: 74) (ICMR, 2020). Figure 8.1 shows the geo-temporal spread in India from 30th January, 2020 to 31th July, 2020. Maharashtra and Tamil Nadu are the major affected states in India.
Updated considerations in the diagnosis and management of tuberculosis infection and disease: integrating the latest evidence-based strategies
Published in Expert Review of Anti-infective Therapy, 2023
Daniel S. Graciaa, Marcos Coutinho Schechter, Krystle B. Fetalvero, Lisa Marie Cranmer, Russell R. Kempker, Kenneth G. Castro
More affordable devices meant to be used in peripheral healthcare settings have also been endorsed by WHO, including the Loopamp MTBC assay and Truenat assays. Loop-mediated isothermal amplification (LAMP) uses an isothermal PCR amplification technique that requires minimal laboratory equipment and while endorsed as replacement to smear microscopy since 2016, has been underutilized to date. The Truenat assays including Truenat MTB Plus and Truenat MTB-RIF Dx (Molbio Diagnostics) run on the Truelab platform, which uses a chip-based, micro-real-time PCR technique that can provide results in 1 h [46]. Initial results are comparable to the Xpert Ultra and the WHO has a conditional recommendation to use Truenat as an initial test for Mtb and rifampicin resistance detection.
Extrapulmonary tuberculosis
Published in Expert Review of Respiratory Medicine, 2021
Surendra K Sharma, Alladi Mohan, Mikashmi Kohli
TrueNat is a product made in India with chip-based, micro real-time PCR-based assays for TB detection that produce results in an hour on the portable Truelab platform (Molbio Diagnostics, Bangalore, India). Truenat MTB, Truenat MTB Plus and Truenat MTB-Rif Dx are three products that have already being rolled out in India and are characterized as a more affordable, made in India alternative to Xpert. Products that are developed and manufactured in-country are often quicker and more straightforward to scale-up, as governments often already have a degree of buy-in, data from locally run studies will have accumulated, and supply chain and regulatory issues are simpler to solve. WHO convened a Guideline Development Group meeting to determine the use of Truenat assays and other rapid molecular tests in December 2019. Results of a multi-center study conducted on pulmonary TB in India are now being analyzed. However, there are no data on EPTB specimens for this platform.
Tuberculosis in the 21th century: Current status of diagnostic methods
Published in Experimental Lung Research, 2018
Patrícia Poeta, Vanessa Silva, Andreia Guedes, José Eduardo Pereira, Ana Cláudia Coelho, Gilberto Igrejas
The Truenat MTB test enables M. tuberculosis DNA detection from samples of patients suspected of TB using a chip. This way a quick diagnosis is achieved. The Truenat MTB test involves the processing and extracting of 5 µl DNA samples in a device known as a Trueprep-MAG which requires a protocol with nanoparticles. Then the extracted DNA is placed in a chip containing stabilized reagents at normal temperature so that the RT-PCR may occur in the Truelab Uno device (basically a portable thermal cycler). Each sample is processed individually on each devide which decreases the contamination probabilities.33 A study conducted by Nikam et al.34 showed that TrueNAT assay shad high concordance with the GeneXpert system. Also, specimens can be tested as soon as a patient presents with symptoms since the Truenat MTB test is battery operated and portable and, therefore, can be operated in locations far from clinical settings.34 A study reported that the Truenat MTB test sensitivity and specificity was 91%, and 100%, respectively. Whereas, among smear-negative, culture-positive specimens, Truenat sensitivity was 76%.35